Antitumorale

Antitumorale refers to substances and strategies aimed at countering tumor growth and progression. In medical usage, antitumorale agents include cytotoxic chemotherapy, targeted therapies such as kinase inhibitors and monoclonal antibodies, hormonal therapies, immunotherapies (for example checkpoint inhibitors and adoptive cellular therapies), anti-angiogenic drugs, radiopharmaceuticals, and certain natural or synthetic compounds with antineoplastic activity. The term is often used in French-language literature and is broadly synonymous with antineoplastic or anticancer methods.

Mechanisms vary: cytotoxic drugs disrupt DNA replication or mitosis; targeted therapies block oncogenic signaling; hormonal therapies interfere with hormone-driven growth; immunotherapies stimulate or harness the immune system to attack cancer cells; anti-angiogenics inhibit tumor blood vessel formation; radiopharmaceuticals deliver radioactive energy to malignant cells; some agents act by epigenetic modification or inducing cancer cell differentiation.

Development and evaluation: Antitumorale therapies undergo preclinical testing and phased clinical trials to determine safety and efficacy. Efficacy endpoints include tumor response rate, progression-free survival, overall survival, and quality of life. Safety profiles depend on the mechanism; common adverse effects include myelosuppression, fatigue, mucositis, neuropathy, gastrointestinal symptoms, and infusion reactions.

Clinical use: Therapy selection depends on tumor type, stage, molecular characteristics, and patient factors. Combination regimens are common to enhance efficacy and overcome resistance but may increase toxicity. The field continually evolves with ongoing research into precision oncology, combination strategies, and biomarkers to predict response.